vs
Side-by-side financial comparison of GE HealthCare (GEHC) and Kenvue (KVUE). Click either name above to swap in a different company.
GE HealthCare is the larger business by last-quarter revenue ($5.7B vs $3.8B, roughly 1.5× Kenvue). GE HealthCare runs the higher net margin — 10.3% vs 8.7%, a 1.6% gap on every dollar of revenue. On growth, GE HealthCare posted the faster year-over-year revenue change (7.1% vs 3.2%). Over the past eight quarters, GE HealthCare's revenue compounded faster (10.7% CAGR vs -1.5%).
GE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures...
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
GEHC vs KVUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.7B | $3.8B |
| Net Profit | $588.0M | $330.0M |
| Gross Margin | 39.7% | 56.5% |
| Operating Margin | 14.5% | 14.2% |
| Net Margin | 10.3% | 8.7% |
| Revenue YoY | 7.1% | 3.2% |
| Net Profit YoY | -18.4% | 12.6% |
| EPS (diluted) | $1.28 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.7B | $3.8B | ||
| Q3 25 | $5.1B | $3.8B | ||
| Q2 25 | $5.0B | $3.8B | ||
| Q1 25 | $4.8B | $3.7B | ||
| Q4 24 | $5.3B | $3.7B | ||
| Q3 24 | $4.9B | $3.9B | ||
| Q2 24 | $4.8B | $4.0B | ||
| Q1 24 | $4.7B | $3.9B |
| Q4 25 | $588.0M | $330.0M | ||
| Q3 25 | $446.0M | $398.0M | ||
| Q2 25 | $486.0M | $420.0M | ||
| Q1 25 | $564.0M | $322.0M | ||
| Q4 24 | $721.0M | $293.0M | ||
| Q3 24 | $470.0M | $383.0M | ||
| Q2 24 | $428.0M | $58.0M | ||
| Q1 24 | $374.0M | $296.0M |
| Q4 25 | 39.7% | 56.5% | ||
| Q3 25 | 38.7% | 59.1% | ||
| Q2 25 | 39.6% | 58.9% | ||
| Q1 25 | 42.1% | 58.0% | ||
| Q4 24 | 42.8% | 56.5% | ||
| Q3 24 | 41.7% | 58.5% | ||
| Q2 24 | 41.4% | 59.1% | ||
| Q1 24 | 40.9% | 57.6% |
| Q4 25 | 14.5% | 14.2% | ||
| Q3 25 | 12.7% | 16.7% | ||
| Q2 25 | 13.1% | 18.0% | ||
| Q1 25 | 13.2% | 14.9% | ||
| Q4 24 | 15.1% | 13.2% | ||
| Q3 24 | 13.9% | 16.8% | ||
| Q2 24 | 12.6% | 3.9% | ||
| Q1 24 | 11.6% | 14.1% |
| Q4 25 | 10.3% | 8.7% | ||
| Q3 25 | 8.7% | 10.6% | ||
| Q2 25 | 9.7% | 10.9% | ||
| Q1 25 | 11.8% | 8.6% | ||
| Q4 24 | 13.6% | 8.0% | ||
| Q3 24 | 9.7% | 9.8% | ||
| Q2 24 | 8.8% | 1.5% | ||
| Q1 24 | 8.0% | 7.6% |
| Q4 25 | $1.28 | $0.16 | ||
| Q3 25 | $0.98 | $0.21 | ||
| Q2 25 | $1.06 | $0.22 | ||
| Q1 25 | $1.23 | $0.17 | ||
| Q4 24 | $1.58 | $0.16 | ||
| Q3 24 | $1.02 | $0.20 | ||
| Q2 24 | $0.93 | $0.03 | ||
| Q1 24 | $0.81 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.5B | $1.1B |
| Total DebtLower is stronger | $10.0B | — |
| Stockholders' EquityBook value | $10.4B | $10.8B |
| Total Assets | $36.9B | $27.1B |
| Debt / EquityLower = less leverage | 0.96× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.5B | $1.1B | ||
| Q3 25 | $4.0B | $1.1B | ||
| Q2 25 | $3.7B | $1.1B | ||
| Q1 25 | $2.5B | $1.1B | ||
| Q4 24 | $2.9B | $1.1B | ||
| Q3 24 | $3.5B | $1.1B | ||
| Q2 24 | $2.0B | $1.0B | ||
| Q1 24 | $2.6B | $1.2B |
| Q4 25 | $10.0B | — | ||
| Q3 25 | $10.3B | — | ||
| Q2 25 | $10.3B | — | ||
| Q1 25 | $8.8B | — | ||
| Q4 24 | $9.0B | — | ||
| Q3 24 | $10.3B | — | ||
| Q2 24 | $9.2B | — | ||
| Q1 24 | $9.3B | — |
| Q4 25 | $10.4B | $10.8B | ||
| Q3 25 | $10.0B | $10.6B | ||
| Q2 25 | $9.7B | $10.7B | ||
| Q1 25 | $9.2B | $10.1B | ||
| Q4 24 | $8.4B | $9.7B | ||
| Q3 24 | $8.3B | $10.6B | ||
| Q2 24 | $7.8B | $10.2B | ||
| Q1 24 | $7.4B | $10.6B |
| Q4 25 | $36.9B | $27.1B | ||
| Q3 25 | $36.1B | $27.2B | ||
| Q2 25 | $35.5B | $27.1B | ||
| Q1 25 | $33.6B | $26.3B | ||
| Q4 24 | $33.1B | $25.6B | ||
| Q3 24 | $33.9B | $26.9B | ||
| Q2 24 | $31.9B | $26.4B | ||
| Q1 24 | $32.2B | $27.3B |
| Q4 25 | 0.96× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 1.06× | — | ||
| Q1 25 | 0.95× | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 1.24× | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | 1.25× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $854.0M |
| Free Cash FlowOCF − Capex | — | $744.0M |
| FCF MarginFCF / Revenue | — | 19.7% |
| Capex IntensityCapex / Revenue | 2.4% | 2.9% |
| Cash ConversionOCF / Net Profit | — | 2.59× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.7B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $854.0M | ||
| Q3 25 | — | $294.0M | ||
| Q2 25 | $94.0M | $621.0M | ||
| Q1 25 | $250.0M | $428.0M | ||
| Q4 24 | — | $793.0M | ||
| Q3 24 | — | $249.0M | ||
| Q2 24 | $-119.0M | $440.0M | ||
| Q1 24 | $419.0M | $287.0M |
| Q4 25 | — | $744.0M | ||
| Q3 25 | — | $196.0M | ||
| Q2 25 | $8.0M | $533.0M | ||
| Q1 25 | $98.0M | $249.0M | ||
| Q4 24 | — | $661.0M | ||
| Q3 24 | — | $190.0M | ||
| Q2 24 | $-183.0M | $350.0M | ||
| Q1 24 | $274.0M | $134.0M |
| Q4 25 | — | 19.7% | ||
| Q3 25 | — | 5.2% | ||
| Q2 25 | 0.2% | 13.9% | ||
| Q1 25 | 2.1% | 6.7% | ||
| Q4 24 | — | 18.1% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | -3.8% | 8.8% | ||
| Q1 24 | 5.9% | 3.4% |
| Q4 25 | 2.4% | 2.9% | ||
| Q3 25 | 2.1% | 2.6% | ||
| Q2 25 | 1.7% | 2.3% | ||
| Q1 25 | 3.2% | 4.8% | ||
| Q4 24 | 1.9% | 3.6% | ||
| Q3 24 | 1.9% | 1.5% | ||
| Q2 24 | 1.3% | 2.3% | ||
| Q1 24 | 3.1% | 3.9% |
| Q4 25 | — | 2.59× | ||
| Q3 25 | — | 0.74× | ||
| Q2 25 | 0.19× | 1.48× | ||
| Q1 25 | 0.44× | 1.33× | ||
| Q4 24 | — | 2.71× | ||
| Q3 24 | — | 0.65× | ||
| Q2 24 | -0.28× | 7.59× | ||
| Q1 24 | 1.12× | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
KVUE
| Self Care | $1.6B | 42% |
| Essential Health | $1.1B | 30% |
| Skin Health And Beauty | $1.0B | 28% |
